The study will use data to track insurance coverage as well as prior authorization requirements for GLP-1 drugs such as Ozempic and Zepbound.
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
One America News Network
Jan 13, 2026 | 11:23 AM
We use cookies for various purposes including analytics and marketing. By continuing to use this service, you agree to use cookies by us and our third-party service providers as described in the Privacy Policy.